Clinical trials
for patients

The purpose of this trial is to continue evaluating whether the investigational drug afimkibart, when administered over a longer period, is safe and effective for moderate-to-severe atopic dermatitis, and to determine the long-term effects, both positive and negative, of afimkibart on atopic dermatitis. You are being asked to participate in this trial because you have moderate-to-severe atopic dermatitis, participated in study CS45570, and responded to treatment with afimkibart.

The objective of this study is to determine whether CPV-104 (the study drug) is safe for use in people (safety), how manageable its side effects are (tolerability), the blood concentrations of CPV-104 and factor H (an important protein in the human body involved in the immune system) (pharmacokinetics), and whether CPV-104 triggers an immune response against foreign substances (immunogenicity).

The objective of this study is to determine whether esketamine is effective in treating adolescents aged 12 to 17 with major depressive disorder who are at imminent risk of suicide. The safety of esketamine in this population will also be evaluated.

The objective of this study is to determine whether combination therapies with the study drugs—that is, ASP3082 and docetaxel, pembrolizumab, or a platinum-based chemotherapy regimen (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab—are safe and effective for treating people with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12D mutation.

This clinical trial is being conducted for research purposes. The study drug VER-01 is being investigated in patients with chronic nonspecific low back pain. The trial includes patients who require treatment for chronic low back pain for whom non-opioid analgesics are not appropriate because of contraindications, provide insufficient pain relief, or are not tolerated.

The objective of this trial is to determine how well a new investigational drug called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib.

The objective of this study is to collect data on the safety of the investigational study medication and to determine how well it works in treating grass pollen allergy.

The primary objective is to evaluate the safety and tolerability of the study drug.

The purpose of the study is to evaluate progression-free survival (PFS) with casdatifan versus placebo, when both are administered in combination with cabozantinib, in adult patients with confirmed advanced or metastatic clear cell renal cell carcinoma who experienced disease progression during or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

This is the first time ODM-216 is being tested in humans. ODM-216 is a type of immunotherapy. It works by helping the immune system better recognize and respond to cancer. The primary objective of this study is to determine the safety and tolerability of ODM-216 and establish the optimal dose.

The purpose of this study is to test several combinations of new investigational drugs (study drugs), with chemotherapy (if you have not yet received treatment for your cancer) or without chemotherapy (if you have already received treatment for your cancer). If you have previously received treatment for colorectal cancer, you may receive the study drug or drugs together with cetuximab.

The primary objective is to evaluate the efficacy of telisotuzumab adizutecan combinations compared with standard treatment in metastatic colorectal cancer (mCRC).

The primary objective of this study is to evaluate the efficacy of the study drug repotrectinib (a kinase inhibitor that blocks the activity of the abnormal ROS1 protein) in patients with NSCLC who have a ROS1 alteration and active brain metastases.

The primary objective is to determine whether proactive neoadjuvant systemic treatment (FOLFOX), with or without HIPEC with mitomycin C, followed by postoperative adjuvant systemic treatment, increases 36-month disease-free survival in patients with locally advanced colon cancer compared with standard treatment.

The primary objective of Part B is to further evaluate the safety of the study drug and how well it is tolerated by the body in a larger number of people with myasthenia gravis (MG). The study will also assess whether the study drug is effective in people with generalized myasthenia gravis (gMG) and ocular myasthenia gravis (oMG).

The purpose of this trial is to test an investigational drug called daraxonrasib (RMC-6236). Daraxonrasib is an investigational drug, which means that it has not been approved by the Spanish Agency for Medicines and Health Products (AEMPS) or by any other health authority in any country. Daraxonrasib is currently being investigated in other ongoing studies in pancreatic cancer, and its safety, tolerability, and efficacy are being evaluated in comparison with usual clinical practice.

The main objectives of the study are as follows: Part A (Phase 1, safety run-in, dose escalation): To determine whether BNT314 in combination with pumitamig can be administered safely without causing serious side effects in participants. Part B (Phase 1, dose optimization): To assess whether BNT314 in combination with pumitamig and standard chemotherapy is safe for participants and to determine the appropriate dose of BNT314 to be used in Part C. Part C (Phase 2, randomization versus standard tr...

The purpose of this clinical study is to determine whether obrixtamig in combination with atezolizumab, carboplatin, and etoposide (standard chemotherapy) is more effective than standard chemotherapy alone in treating people with advanced small cell lung cancer.